Literature DB >> 21481825

Effect of experience on results of transcatheter aortic valve implantation using a Medtronic CoreValve System.

Rutger-Jan Nuis1, Nicolas M van Mieghem, Robert M van der Boon, Robert-Jan van Geuns, Carl J Schultz, Frans B Oei, Tjebbe W Galema, Goris Bol Raap, Peter J Koudstaal, Marcel L Geleijnse, Arie Pieter Kappetein, Patrick W Serruys, Peter P de Jaegere.   

Abstract

Outcome after transcatheter aortic valve implantation (TAVI) depends on the patient risk profile, operator experience, progress in technology, and technique. We sought to compare the results of TAVI during the initiation phase and after certification to perform TAVI with the Medtronic CoreValve System without proctoring. A total of 165 consecutive patients was categorized into a first cohort of 33 patients treated before certification (November 2005 to December 2007) and a second cohort of 132 patients treated after certification (January 2008 to October 2010). The study end points were selected and defined according to the Valve Academic Research Consortium recommendations. Compared to cohort 2, the patients in cohort 1 more frequently had New York Heart Association class III-IV (100% vs 71%, p <0.001), hypertension (67% vs 39%, p = 0.004), and aortic regurgitation grade III-IV (46% vs 22%, p = 0.006) before TAVI. Over time, the patients in cohort 2 more frequently underwent a truly percutaneous approach (98% vs 82%, p = 0.002) without circulatory support (96% vs 67%, p <0.001) but with more concomitant percutaneous coronary intervention (11% vs 0%, p = 0.042) than the patients in cohort 1. They also more often received a 29-mm prosthesis (72% vs 24%, p <0.001), required less postimplantation balloon dilation (10% vs 27%, p = 0.008), and had less aortic regurgitation grade III-IV after TAVI (12% vs 30%, p = 0.010). The clinical outcome showed a nonsignificant reduction in the combined safety end point (30% to 17%) but a significant reduction in cerebrovascular events (21% to 7%, p = 0.020) and life-threatening bleeding (15% to 5%, p = 0.044) in cohort 2. However, the reduction in overall bleeding and vascular complications (25% and 14%, respectively) was not significant. In conclusion, TAVI became significantly less complex and was associated with better results over time but remained associated with a high frequency of periprocedural major cardiovascular complications. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21481825     DOI: 10.1016/j.amjcard.2011.02.315

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

Review 1.  TAVI 2012: state of the art.

Authors:  Jochen Reinöhl; Constantin von Zur Mühlen; Martin Moser; Stefan Sorg; Christoph Bode; Manfred Zehender
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

2.  Transcatheter Aortic Valve Implantation in Taiwan: Still Evolving!

Authors:  Wei-Hsian Yin
Journal:  Acta Cardiol Sin       Date:  2017-07       Impact factor: 2.672

3.  Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis.

Authors:  Thomas Pilgrim; Stefan Stortecky; Fabienne Luterbacher; Stephan Windecker; Peter Wenaweser
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

4.  [Certification : Pro: indispensable component of quality].

Authors:  M Halbach; S Baldus
Journal:  Herz       Date:  2018-09       Impact factor: 1.443

5.  Colombian experience with transcatheter aortic valve implantation of medtronic CoreValve.

Authors:  Antonio E Dager; Rutger-Jan Nuis; Bernardo Caicedo; Jaime A Fonseca; Camilo Arana; Lidsa Cruz; Luis M Benitez; Carlos A Nader; Eduardo Duenas; Eduardo J de Marchena; William W O'Neill; Peter P de Jaegere
Journal:  Tex Heart Inst J       Date:  2012

6.  Association of Transcatheter Aortic Valve Replacement With 30-Day Renal Function and 1-Year Outcomes Among Patients Presenting With Compromised Baseline Renal Function: Experience From the PARTNER 1 Trial and Registry.

Authors:  Nirat Beohar; Darshan Doshi; Vinod Thourani; Hanna Jensen; Susheel Kodali; Feifan Zhang; Yiran Zhang; Charles Davidson; Patrick McCarthy; Michael Mack; Samir Kapadia; Martin Leon; Ajay Kirtane
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

7.  Patient selection for transcatheter aortic valve implantation: An interventional cardiology perspective.

Authors:  Darrren Mylotte; Giuseppe Martucci; Nicolo Piazza
Journal:  Ann Cardiothorac Surg       Date:  2012-07

8.  Patients with aortic stenosis referred for TAVI: treatment decision, in-hospital outcome and determinants of survival.

Authors:  R J Nuis; A E Dager; R M van der Boon; M C Jaimes; B Caicedo; J Fonseca; N M Van Mieghem; L M Benitez; J P Umana; W W O'Neill; E de Marchena; P P de Jaegere
Journal:  Neth Heart J       Date:  2012-01       Impact factor: 2.380

9.  Prediction of paravalvular leakage after transcatheter aortic valve implantation.

Authors:  Luigi F M Di Martino; Wim B Vletter; Ben Ren; Carl Schultz; Nicolas M Van Mieghem; Osama I I Soliman; Matteo Di Biase; Peter P de Jaegere; Marcel L Geleijnse
Journal:  Int J Cardiovasc Imaging       Date:  2015-07-18       Impact factor: 2.357

10.  Recent advances in transcatheter aortic valve implantation: novel devices and potential shortcomings.

Authors:  J Blumenstein; C Liebetrau; A Van Linden; H Moellmann; T Walther; J Kempfert
Journal:  Curr Cardiol Rev       Date:  2013-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.